Immunology and treatment of atopic dermatitis

American Journal of Clinical Dermatology

Volumn 9, Issue 4, 2008, Pages 233-244

  Spergel, Jonathan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atopic dermatitis, treatment; Calcineurin inhibitors, therapeutic use; Corticosteroids, therapeutic use; Pimecrolimus, therapeutic use; Tacrolimus, therapeutic use

Indexed keywords

BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CLOBETASOL; CORTICOSTEROID; DIFLUCORTOLONE; FLUTICASONE PROPIONATE; IMMUNOMODULATING AGENT; PIMECROLIMUS; PREDNICARBATE; TACROLIMUS;

ADRENAL SUPPRESSION; ATOPIC DERMATITIS; BURN; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; GROWTH INHIBITION; HEREDITY; HUMAN; HYPERTRICHOSIS; IMMUNE SYSTEM; INJECTION SITE REACTION; LYMPHOMA; MONOTHERAPY; NONHUMAN; PERIORAL DERMATITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; ROSACEA; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN CARE; SKIN INFECTION; STRIA; T LYMPHOCYTE ACTIVATION; TELANGIECTASIA;

ADRENAL CORTEX HORMONES; CALCINEURIN; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; EMOLLIENTS; HUMANS; HYGIENE; IMMUNOSUPPRESSIVE AGENTS;

EID: 45949098821     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809040-00003     Document Type: Review

References (122)

1. Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000; 43 (4): 649-55
2. Larsen FS, Hanifin JM. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002; 22 (1): 1-24
3. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005; 6 (2): 65-77
4. Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol 2005; 22 (3): 192-9
5. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health R I 2001; 84 (9): 294-5
6. Paller AS, McAlister RO, Doyle JJ, et al. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila) 2002; 41 (5): 323-32
7. Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996; 7: 149-54
8. Fivenson D, Arnold RJG, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002; 8 (5): 333-42
9. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46 (3): 361-70
10. Peroni DG, Piacentini GL, Alfonsi L, et al. Rhinitis in pre-school children: prevalence, association with allergic diseases and risk factors. Clin Exp Allergy 2003; 33 (10): 1349-54
11. Porsbjerg C, von Linstow ML, Ulrik CS, et al. Risk factors for onset of asthma: a 12-year prospective follow-up study. Chest 2006; 129 (2): 309-16
12. Bergmann RL, Edenharter G, Bergmann KE, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 1998; 28 (8): 965-70
13. Iikura Y, Naspitz CK, Mikawa H, et al. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy 1992; 68 (3): 233-6
14. Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol 2001; 108 (6): 929-37
15. Gustafsson D, Sjöberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis: a prospective follow-up to 7 years of age. Allergy 2000; 55 (3): 240-5
16. Gustafsson D, Sjöberg O, Foucard T. Sensitization to food and airborne allergens in children with atopic dermatitis followed up to 7 years of age. Pediatr Allergy Immunol 2003; 14 (6): 448-52
17. Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003; 112 (6 Suppl.): S128-39
18. Kusel MM, Holt PG, de Klerk N, et al. Support for 2 variants of eczema. J Allergy Clin Immunol 2005; 116 (5): 1067-72
19. Schafer T, Kramer U, Vieluf D, et al. The excess of atopic eczema in East Germany is related to the intrinsic type. Br J Dermatol 2000; 143 (5): 992-8
20. Novembre E, Cianferoni A, Lombardi E, et al. Natural history of 'intrinsic' atopic dermatitis. Allergy 2001; 56 (5): 452-3
21. Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004; 4: 978-88
22. Abramovits W. A clinician's paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol 2005; 53 (1 Suppl.): S70-7
23. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003; 361 (9352): 151-60
24. Morar N, Willis-Owen SA, Moffatt MF, et al. The genetics of atopic dermatitis. J Allergy Clin Immunol 2006; 118 (1): 24-34
25. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006; 118 (1): 3-21
26. Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol 2006; 126 (6): 1200-2
27. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38 (4): 441-6
28. Kim DW, Park JY, Na GY, et al. Correlation of clinical features and skin barrier function in adolescent and adult patients with atopic dermatitis. Int J Dermatol 2006; 45 (6): 698-701
29. Chamlin SL, Frieden IJ, Fowler A, et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 2001; 137 (8): 1110-2
30. Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 1983; 80 Suppl.: 44-49s
31. Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med J 2006; 47 (3): 293-306
32. Rawlings AV. Trends in stratum corneum research and the management of dry skin conditions. Int J Cosmetic Sci 2003; 25: 63-95
33. Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 1991; 96 (4): 523-6
34. Proksch E, Folster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006; 43 (3): 159-69
35. Coderch L, Lopez O, de la Maza A, et al. Ceramides and skin function. Am J Clin Dermatol 2003; 4 (2): 107-29
36. Jensen JM, Folster-Holst R, Baranowsky A, et al. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004; 122 (6): 1423-31
37. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2007; 120 (1): 150-5
38. Breuer K, Häussler S, Kapp A, et al. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. Br Dermatol 2002; 147 (1): 55-61
39. Caproni M, Torchia D, Antiga E, et al. The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol 2006; 26 (4): 370-5
40. Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005; 116 (5): 961-8
41. Simpson EL, Hanifin JM. Atopic dermatitis. Med Clin North Am 2006; 90 (1): 149-67
42. Leung DYM, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113 (5): 651-7
43. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994; 94 (2): 870-6
44. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3 (7): 673-80
45. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107 (3): 535-41
46. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299 (5609): 1057-61
47. Verhagen J, Akdis M, Traidl-Hoffmann C, et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006; 117 (1): 176-83
48. Ou LS, Goleva E, Hall C, et al. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J Allergy Clin Immunol 2004; 113 (4): 756-63
49. Vukmanovic-Stejic M, McQuaid A, Birch KE, et al. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis. Br J Dermatol 2005; 153 (4): 750-7
50. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347 (15): 1151-60
51. Howell MD, Novak N, Bieber T, et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis. J Invest Dermatol 2005; 125 (4): 738-45
52. Ilhan F, Kandi B, Akbulut H, et al. Atopic dermatitis and Vα24+ natural killer T cells. Skinmed 2007; 6 (5): 218-20
53. Cardona ID, Cho SH, Leung DY. Role of bacterial superantigens in atopic dermatitis: implications for future therapeutic strategies. Am J Clin Dermatol 2006; 7 (5): 273-9
54. Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003; 148 Suppl. 63: 3-10
55. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Ann Allergy Asthma Immunol 2004; 93 (3 Suppl. 2): S1-21
56. Correale CE, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999; 60 (4): 1191-8
57. Abramovits W, Gover MD, Gupta AK. Atopiclair nonsteroidal cream. Skinmed 2005; 4 (6): 369
58. Abramovits W, Perlmutter A. MimyX cream. Skinmed 2006; 5 (1): 29-30
59. Ceragenix Pharmaceuticals I. Epiceram® skin barrier emulsion: 510(k) summary [online]. Available from URL: http://www.fda.gov/cdrh/pdf5/K052643.pdf [Accessed 2007 Aug 28]
60. Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy 2004; 59 Suppl. 78: 86-92
61. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol 2004; 50 (3): 391-404
62. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005; 53 (1 Suppl. 1): S17-25
63. Hughes J, Rustin M. Corticosteroids. Clin Dermatol 1997; 15 (5): 715-21
64. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336 (15): 1066-71
65. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002; 966: 290-303
66. Buske-Kirschbaum A, Ebrecht M, Kern S, et al. Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris): do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis)? Psychoneuroendocrinology 2006; 31 (4): 439-46
67. Heasman SJ, Giles KM, Ward C, et al. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J Endocrinol 2003; 178 (1): 29-36
68. Liu Y, Cousin JM, Hughes J, et al. Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 1999; 162 (6): 3639-46
69. Sulzberger MB, Witten VH, Smith CC. Hydrocortisone (compound F) acetate ointment in dermatological therapy. JAMA 1953; 151 (6): 468-72
70. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003; 112 (6 Suppl.): S140-50
71. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986; 115 (4): 475-84
72. Berger TG, Duvic M, Van Voorhees AS, et al., for the American Academy of Dermatology. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54 (5): 818-23
73. Aalto-Korte K, Turpeinen M. Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis. Br J Dermatol 1995; 133 (2): 259-63
74. Maibach HI. In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy. Dermatologica 1976; 152 Suppl. 1: 11-25
75. Maibach HI, Wester RC. Issues in measuring percutaneous absorption of topical corticosteroids. Int J Dermatol 1992; 31 Suppl. 1: 21-5
76. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981): preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20 (4): 233-41
77. Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141 (2): 264-73
78. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211 (2): 174-87
79. Astellas Pharma US, Inc. Protopic® [prescribing information]. Deerfield (IL): Astellas Pharma US, Inc., 2006 [online]. Available from URL: http://www.astellas.us/docs/protopic.pdf [Accessed 2007 Aug 28]
80. Novartis Pharmaceuticals. Elidel® [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals, 2006 [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/elidel.pdf [Accessed 2007 Aug 28]
81. Crabtree GR. Calcium, calcineurin, and the control of transcription. J Biol Chem 2001; 276 (4): 2313-6
82. Schulz BS, Michel G, Wagner S, et al. Increased expression of epidermal IL-8 receptor in psoriasis: down-regulation by FK-506 in vitro. J Immunol 1993; 151 (8): 4399-406
83. Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107 (3): 519-25
84. de Paulis A, Stellato C, Cirillo R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992; 99 (6): 723-8
85. Aberer W, Romani N, Elbe A, et al. Effects of physicochemical agents on murine epidermal Langerhans cells and Thy-1-positive dendritic epidermal cells. J Immunol 1986; 136 (4): 1210-6
86. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122 (3): 673-84
87. Hoetzenecker W, Ecker R, Kopp T, et al. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005; 115 (6): 1276-83
88. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 1995; 105 (1 Suppl.): 84-88S
89. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (1 Suppl.): S58-64
90. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102 (4 Pt 1): 637-44
91. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 (1 Suppl.): S47-57
92. Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Derma tol 2000; 136 (8): 999-1006
93. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337 (12): 816-21
94. Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol 2006; 7 (2): 121-31
95. Breuer K, Braeutigam M, Kapp A, et al. Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis. Dermatology 2004; 209 (4): 314-20
96. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46 (4): 495-504
97. Meurer M, Fölster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205 (3): 271-7
98. Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208 (4): 365-72
99. Papp KA, Werfel T, Fölster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005; 52 (2): 240-6
100. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110 (1 Pt 1): e2
101. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics reviews: Protopic (tacrolimus) ointment. Application number NDA 50-777, 2000 Oct 2 [online]. Available from URL: http://www.fda.gov/cder/foi/ nda/2000/50777_Protopic_BioPharma_P1.pdf [Accessed 2007 Aug 28]
102. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124 (4): 695-9
103. Van Leent EJM, Ebelin M-E, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002; 204 (1): 63-8
104. Thaçi D, Steinmeyer K, Ebelin M-E, et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective: an open study. Dermatology 2003; 207 (1): 37-42
105. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003; 88 (11): 969-73
106. Billich A, Aschauer H, Aszódi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269 (1): 29-35
107. Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 2006; 6 (4): 270-4
108. US Food and Drug Administration. FDA approves updated labeling with boxed warning and medication guide for two eczema drugs, Elidel and Protopic (press release no. P06-09), 2006 Jan 19 [online]. Available from URL: http://www.fda.gov/bbs/topcs/news/2006/NEW01299.html [Accessed 2007 Aug 28]
109. Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211 (2): 77-8
110. Margolis D, Ole H, Bilker W. Is there an association between the use of topical calcineurin inhibitors and skin cancer [abstract no. 285]? 67th Annual Meeting of the Society for Investigative Dermatology; 2006 May 3-6; Philadelphia (PA). J Invest Dermatol 2006; 126 Suppl. 4: 1-156
111. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005; 115 (6): 1249-53
112. Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: portion statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005; 19 (6): 663-71
113. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-16
114. Huang X, Tanojo H, Lenn J, et al. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005; 53 (1 Suppl. 1): S26-38
115. Furue M, Terao H, Moroi Y, et al. Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis. J Dermatol 2004; 31 (4): 277-83
116. Nakahara T, Koga T, Fukagawa S, et al. Intermittent topical corticosteroid/ tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/ emollient sequential therapy in patients with atopic dermatitis. J Dermatol 2004; 31 (7): 524-8
117. Gupta A. The use of combination prednicarbate/tacrolimus versus tacrolimus alone to treat atopic dermatitis in children [abstract no. P734]. 63rd Annual Meeting of the American Academy of Dermatology; 2005 Feb 18-22; New Orleans (LA). J Am Acad Dermatol 2005; 52 (3): P74
118. Blum RR, Berman B, Koo J, Lebwohl M. An evaluation of the concurrent use of fluticasone and tacrolimus ointments in the treatment of atopic dermatitis [poster]. Summer American Academy meeting; 2004 Jul 28-Aug 4; New York
119. Spergel JM, Boguniewicz M, Paller AS, et al. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. Br J Dermatol 2007; 157 (2): 378-81
120. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118 (1): 152-69
121. Hernández-Segura AM, Téllez BH, Ramírez- González MD. Participation of epidermal Langerhans cells in human pathology and their potential as targets for drug development: a review of literature. Proc West Pharmacol Soc 2005; 48: 13-20
122. Beissert S, Cavazzana I, Mascia F, et al. Mechanisms of immune-mediated skin diseases: an overview. Clin Exp Rheumatol 2006; 24 (1 Suppl. 40): S1-6